Calithera Biosciences (NASDAQ:CALA) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.24) by 20.83 percent. This is a 34.48 percent increase over losses of $(0.29) per share from the same period last year. The company reported $3.00 million in sales this quarter.
Calithera Biosciences Q2 EPS $(0.19) Beats $(0.24) Estimate, Sales $3.00M
Calithera Biosciences (NASDAQ:CALA) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.24) by 20.83 percent. This is a 34.48 percent increase over losses of $(0.29) per share
